Top Markets
#1 Tutorial Tutorial +45.75%
#2 Siacoin Siacoin +28.41%
#3 Official Trump Official Trump +20.74%
#4 Unit Pump Unit Pump +20.47%
#5 Pump.fun Pump.fun +20.47%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +20.32%
#7 EXOD EXOD +18.93%
#8 MowCat MowCat +17.72%
#9 Stacks Stacks +15.29%
#10 Mubarak Mubarak +14.29%
Coin of the day
Tutorial Tutorial
Settings
Language
ENGLISH
Currency
USD
Theme
Energenesis Biomedical CO.,LTD. Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD.

6657
Rank in Stocks #22642
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered... Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
Share Price
$0.97305026
Last synced: 2026-08-21
Market Cap
$85.54M
Change (1 day)
1.16%
Change (1 year)
-50.40%
Country
TW
Trade Energenesis Biomedical CO.,LTD. (6657)

Category

Healthcare
P/E ratio for Energenesis Biomedical CO.,LTD. (6657)
P/E ratio as of 2026 TTM: 0
According to Energenesis Biomedical CO.,LTD. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Energenesis Biomedical CO.,LTD. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.